Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03439514 · ClinicalTrials.gov registry record · Phase 3
A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 77
- Enrollment target
NCT03439514 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 77 participants.
The verdict
NCT03439514, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 77 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study in patients with dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA). The study will further evaluate a dose level of study drug (ARRY-371797) that has shown preliminary efficacy and safety in this patient population. After the primary analysis has been performed, eligible patients may receive open-label treatment with ARRY-371797.
Interventions
- OTHER Placebo
- DRUG ARRY-371797 (PF-07265803)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2018-04-17 |
| Est. Completion | 2022-10-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03439514
The ClinicalTrials.gov registry entry for NCT03439514 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03439514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03439514 about?
NCT03439514 is a clinical study titled "A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation". This is a randomized, double-blind, placebo-controlled study in patients with dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA). The study will further evaluate a dose level of study drug (ARRY-371797) that has shown preliminary efficacy and safety in t...
What is the current status of trial NCT03439514?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 77 participants. The study started on 2018-04-17. Estimated completion is 2022-10-13.
What interventions are being tested in trial NCT03439514?
The interventions under investigation include: Placebo (OTHER), ARRY-371797 (PF-07265803) (DRUG).
Who is sponsoring clinical trial NCT03439514?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.